Celebrating 10 years of Molly

Summary

Marking 10 years of Molly on the market as a commercialized product, this interview reflects SHL Medical’s approach to advancing self-injection through platform-based design and long-term customer collaboration. Built on decades of autoinjector expertise, Molly was developed as a reliable, scalable solution with a simple 2-step injection mechanism. It has since evolved to support a wide range of drug-device combination products, including higher-volume biologics, enabled by a modular, standardized platform designed for consistent performance at scale.

Key takeaways

• Built on more than 35 years of autoinjector engineering experience, the 2-step injection mechanism is designed for simplicity and reliability.
• Developed through continuous collaboration with pharma partners.
• Platform approach enables standardization with targeted customization.
• Supports high-volume biologics, including ≥2.0 mL combination products.
• Enables more than 20 approved combination products across nearly 30 indications.
• Proven reliability supported by low complaint rates and real-world performance.
• Vertical integration supports scalability and reduces total cost of ownership.
• Bio-based option reduces carbon emissions while maintaining performance.
• Continued investment in global manufacturing and platform development.

Document details

• Format: executive interview
• Author/Spokesperson: Nicholas Heaton, Global Head of Sales
• Page count: 5 pages
• Estimated read time: ~10–11 minutes